Catalogusnummer
|
Chemische naam
|
EG-nr.
|
CAS-nr.
|
Indeling
|
Etikettering
|
Specifieke concentratiegrenzen, M-factoren en ATE’s
|
Opmerkingen
|
Gevarenklasse en -categorie
|
Gevarenaanduiding
|
Pictogram, signaalwoord
|
Gevarenaanduiding
|
Aanvullende gevarenaanduiding
|
“005-022-00-4
|
perboorzuur, natriumzout [1]
perboorzuur, natriumzout, monohydraat [2],
perboorzuur (HBO(O2)), natriumzout, monohydraat [3] natriumperoxoboraat [4],
natriumperboraat [5]
|
234-390-0 [1]
234-390-0 [2]
— [3]
— [4]
239-172-9 [5]
|
11138-47-9 [1]
12040-72-1 [2]
10332-33-9 [3]
— [4]
15120-21-5 [5]
|
Ox. Sol. 3
Repr. 1B
Acute Tox. 3
Acute Tox. 4
STOT SE 3
Eye Dam. 1
|
H272
H360FD
H331
H302
H335
H318
|
GHS03
GHS08
GHS06
GHS05
Dgr
|
H272
H360FD
H331
H302
H335
H318
|
|
inademing: ATE = 0,75 mg/l (stofdeeltjes of nevels)
oraal: ATE = 890 mg/kg lg
Eye Dam. 1; H318:
C ≥ 22 %
Eye Irrit. 2; H319:
14 % ≤ C < 22 %
|
11”
|
“005-023-00-X
|
perboorzuur (H3BO2(O2)), mononatriumzout, trihydraat [1]
perboorzuur, natriumzout, tetrahydraat [2]
perboorzuur (HBO(O2)), natriumzout, tetrahydraat [3] natriumperoxoboraat, hexahydraat [4]
|
239-172-9 [1]
234-390-0 [2]
— [3]
— [4]
|
13517-20-9 [1]
37244-98-7 [2]
10486-00-7 [3]
— [4]
|
Repr. 1B
Acute Tox. 4
STOT SE 3
Eye Dam. 1
|
H360FD
H332
H335
H318
|
GHS08
GHS05
GHS07
Dgr
|
H360FD
H332
H335
H318
|
|
inademing: ATE = 1,2 mg/l (stofdeeltjes of nevels)
Eye Dam. 1; H318: C ≥ 36 %
Eye Irrit. 2; H319: 22 % ≤ C < 36 %
|
11”
|
“005-024-00-5
|
natriumperoxometaboraat
|
231-556-4
|
7632-04-4
|
Ox. Sol. 2
Repr. 1B
Acute Tox. 3
Acute Tox. 4
STOT SE 3
Eye Dam. 1
|
H272
H360FD
H331
H302
H335
H318
|
GHS03
GHS08
GHS06
GHS05
Dgr
|
H272
H360FD
H331
H302
H335
H318
|
|
inademing: ATE = 0,62 mg/l (stofdeeltjes of nevels)
oraal: ATE = 730 mg/kg lg
Eye Dam. 1; H318:
C ≥ 22 %
Eye Irrit. 2; H319: 14 % ≤ C < 22 %
|
11”
|
“006-104-00-2
|
meerwandige koolstofbuizen (synthetisch grafiet in buisvorm) met een geometrische buisdiameter ≥ 30 nm tot < 3 μm en een lengte ≥ 5 μm en een dimensieverhouding > 3:1, met inbegrip van meerwandige koolstofnanobuizen, MWC(N)T
|
—
|
—
|
Carc. 1B
STOT RE 1
|
H350i
H372 (long) (inademing)
|
GHS08
Dgr
|
H350i
H372 (long) (inademing)
|
|
STOT RE 1; H372: C ≥ 1 %;
STOT RE 2; H373: 0,1 % ≤ C < 1 %”
|
|
“029-026-00-0
|
koper; [specifieke oppervlakte > 0,67 mm2/mg]
|
231-159-6
|
7440-50-8
|
Aquatic Acute 1
Aquatic Chronic 1
|
H400
H410
|
GHS09
Wng
|
H410
|
|
M = 10
M = 1”
|
|
“047-004-00-9
|
massief zilver: [deeltjesdiameter ≥ 1 mm]
|
231-131-3
|
7440-22-4
|
Repr. 2
STOT RE 2
|
H361f
H373 (zenuwstelsel)
|
GHS08
Wng
|
H361f
H373 (zenuwstelsel)”
|
|
|
|
“047-005-00-4
|
zilverpoeder: [deeltjesdiameter > 100 nm < 1 mm]
|
231-131-3
|
7440-22-4
|
Repr. 2
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
|
H361f
H373 (zenuwstelsel)
H400
H410
|
GHS08
GHS09
Wng
|
H361f
H373 (zenuwstelsel)
H410
|
|
M = 10
M = 10”
|
|
“047-006-00-X
|
nanozilver: [deeltjesdiameter > 1 nm ≤ 100 nm]
|
231-131-3
|
7440-22-4
|
Repr. 2
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
|
H361f
H373 (zenuwstelsel)
H400
H410
|
GHS08
GHS09
Wng
|
H361f
H373 (zenuwstelsel)
H410
|
|
M = 1 000
M = 1 000 ”
|
|
“603-247-00-8
|
reactiemassa van 1,3-dioxaan-5-ol en 1,3-dioxolaan-4-ylmethanol
|
—
|
—
|
Repr. 1B
|
H360Df
|
GHS08
Dgr
|
H360Df”
|
|
|
|
“605-042-00-9
|
α-methyl-1,3-benzodioxool-5-propionaldehyde [1]
(S)-α-methyl-1,3-benzodioxool-5-propionaldehyde;
(2S)-3-(1,3-benzodioxool-5-yl)-2-methylpropanal [2]
(R)-α-methyl-1,3-benzodioxool-5-propionaldehyde;
(2R)-3-(1,3-benzodioxool-5-yl)-2-methylpropanal [3]
|
214-881-6 [1]
— [2]
— [3]
|
1205-17-0 [1]
737776-68-0 [2]
737776-59-9 [3]
|
Skin Sens. 1B
|
H317
|
GHS07
Wng
|
H317”
|
|
|
|
“605-043-00-4
|
2,4-dimethylcyclohex-3-een-1-carbaldehyde [1]
(1α,2α,5α)-2,5-dimethylcyclohex-3-een-1-carbaldehyde [2]
2,6-dimethylcyclohex-3-een-1-carbaldehyde [3]
3,5-dimethylcyclohex-3-een-1-carbaldehyde [4]
3,6-dimethylcyclohex-3-een-1-carbaldehyde [5]
4,6-dimethylcyclohex-3-een-1-carbaldehyde [6]
reactiemassa van 3,5-dimethylcyclohex-3-een-1-carbaldehyde en 2,4-dimethylcyclohex-3-een-1-carbaldehyde [7]
dimethylcyclohex-3-een-1-carbaldehyde [8]
dimethylcyclohex-3-een-1-carbaldehyde [9]
1,2,4(of 1,3,5)-trimethylcyclohex-3-een-1-carbaldehyde [10]
1,3,4-trimethylcyclohex-3-een-1-carbaldehyde [11]
2,2,4-trimethylcyclohex-3-een-1-carbaldehyde [12]
2,4,6-trimethylcyclohex-3-eencarbaldehyde [13]
isocyclocitral [14]
3,5,6-trimethylcyclohex-3-een-1-carbaldehyde [15]
4,6,6-trimethylcyclohex-3-een-1-carbaldehyde [16]
|
268-264-1 [1]
252-395-6 [2]
— [3]
268-263-6 [4]
267-186-5 [5]
253-139-6 [6]
— [7]
248-742-6 [8]
272-113-5 [9]
276-055-1 [10]
— [11]
— [12]
215-833-7 [13]
215-638-7 [14]
266-810-3 [15]
— [16]
|
68039-49-6 [1]
35145-02-9 [2]
6975-94-6 [3]
68039-48-5 [4]
67801-65-4 [5]
36635-35-5 [6]
— [7]
27939-60-2 [8]
68737-61-1 [9]
71832-78-5 [10]
40702-26-9 [11]
1726-47-2 [12]
1423-46-7 [13]
1335-66-6 [14]
67634-07-5 [15]
6754-27-4 [16]
|
Skin Sens. 1
|
H317
|
GHS07
Wng
|
H317”
|
|
|
|
“606-156-00-1
|
acetonoxim
|
204-820-1
|
127-06-0
|
Carc. 1B
Acute Tox. 4
STOT SE 3
STOT RE 2
Eye Dam. 1
Skin Sens. 1
|
H350
H312
H336
H373 (bloed)
H318
H317
|
GHS08
GHS07
GHS05
Dgr
|
H350
H312
H336
H373 (bloed)
H318
H317
|
|
dermaal: ATE = 1 100 mg/kg lg”
|
|
“606-157-00-7
|
(3E)-dec-3-een-2-on
|
—
|
18402-84-1
|
Acute Tox. 4
Asp. Tox. 1
Skin Irrit. 2
Aquatic Chronic 2
|
H332
H304
H315
H411
|
GHS07
GHS08
GHS09
Dgr
|
H332
H304
H315
H411
|
EUH071
|
inademing: ATE = 1,5 mg/l (stofdeeltjes of nevels)”
|
|
“606-158-00-2
|
2-(dimethylamino)-2-[(4-methylfenyl)methyl]-1-[4-(morfoline-4-yl)fenyl]butaan-1-on
|
438-340-0
|
119344-86-4
|
Repr. 1B
Aquatic Acute 1
Aquatic Chronic 1
|
H360Df
H400
H410
|
GHS08
GHS09
Dgr
|
H360Df
H410
|
|
M = 1
M = 1”
|
|
“607-770-00-2
|
2,3-epoxypropylneodecanoaat
|
247-979-2
|
26761-45-5
|
Muta. 2
Skin Sens. 1A
|
H341
H317
|
GHS08
GHS07
Wng
|
H341
H317
|
|
Skin Sens. 1A; H317: C ≥ 0,001 %”
|
|
“607-771-00-8
|
benthiavalicarb-isopropyl (ISO); isopropyl-[(S)-1-{[(R)-1-(6-fluor-1,3-benzothiazool-2-yl)ethyl]carbamoyl}-2-methylpropyl]carbamaat
|
—
|
177406-68-7
|
Carc. 1B
Repr. 2
Skin Sens. 1
Aquatic Chronic 2
|
H350
H361fd
H317
H411
|
GHS08
GHS07
GHS09
Dgr
|
H350
H361fd
H317
H411”
|
|
|
|
“607-772-00-3
|
hexylsalicylaat
|
228-408-6
|
6259-76-3
|
Repr. 2
Skin Sens. 1
|
H361d
H317
|
GHS08
GHS07
Wng
|
H361d
H317”
|
|
|
|
“607-773-00-9
|
7-oxabicyclo[4.1.0]hept-3-ylmethyl-7-oxabicyclo[4.1.0]heptaan-3-carboxylaat
|
219-207-4
|
2386-87-0
|
Muta. 2
STOT RE 2
Skin Sens. 1
|
H341
H373 (neusholte)
H317
|
GHS08
GHS07
Wng
|
H341
H373 (neusholte)
H317”
|
|
|
|
“607-774-00-4
|
tetranatrium-4-amino-5-hydroxy-3,6-bis [[4-[[2-(sulfonatoöxy)ethyl]sulfonyl]fenyl]azo]naftaleen-2,7-disulfonaat [1]
reactieproducten van 4-amino-5-hydroxynaftaleen-2,7-disulfonzuur, tweemaal gekoppeld met gediazoteerd 2-[(4-aminofenyl)sulfonyl]ethylhydrogeensulfaat, natriumzouten [2]
dinatrium-4-amino-5-hydroxy-3,6-bis{[4-(vinylsulfonyl)fenyl]diazenyl}naftaleen-2,7-disulfonaat [3]
|
d241-164-5 [1]
— [2]
— [3]
|
17095-24-8 [1]
— [2]
100556-82-9 [3]
|
Resp. Sens. 1A
Skin Sens. 1
|
H334
H317
|
GHS08
Dgr
|
H334
H317”
|
|
|
|
“607-775-00-X
|
natrium-3-(allyloxy)-2-hydroxypropaansulfonaat
|
258-004-5
|
52556-42-0
|
Repr. 1B
Eye Dam. 1
|
H360F
H318
|
GHS08
GHS05
Dgr
|
H360F
H318”
|
|
|
|
“609-074-00-4
|
1,4-dichloor-2-nitrobenzeen
|
201-923-3
|
89-61-2
|
Carc. 1B
|
H350
|
GHS08
Dgr
|
H350”
|
|
|
|
“611-182-00-1
|
2-[ethyl[3-methyl-4-[(5-nitrothiazool-2-yl)azo]fenyl]amino]ethanol
|
271-183-4
|
68516-81-4
|
Skin Sens. 1A
|
H317
|
GHS07
Wng
|
H317
|
|
Skin Sens. 1A; H317: C ≥ 0,001 %”
|
|
“612-299-00-0
|
fenpropidin (ISO); (R,S)-1-[3-(4-tert-butylfenyl)-2-methylpropyl]piperidine
|
—
|
67306-00-7
|
Repr. 2
Acute Tox. 4
Acute Tox. 4
STOT SE 3
STOT SE 3
STOT RE 2
Skin Irrit. 2
Eye Dam. 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H361d
H332
H302
H335
H336
H373 (zenuwstelsel, ogen, longen)
H315
H318
H317
H400
H410
|
GHS08
GHS07
GHS05
GHS09
Dgr
|
H361d
H332
H302
H335
H336
H373 (zenuwstelsel, ogen, longen)
H315
H318
H317
H410
|
|
Inademing: ATE = 1,2 mg/l (stofdeeltjes of nevels)
oraal: ATE = 1 330 mg/kg lg
M = 1 000
M = 10 000 ”
|
|
“613-350-00-X
|
1H-benzotriazool
|
202-394-1
|
95-14-7
|
Aquatic Chronic 2
|
H411
|
GHS09
Wng
|
H411”
|
|
|
|
“613-351-00-5
|
methyl-1H-benzotriazool
|
249-596-6
|
29385-43-1
|
Aquatic Chronic 2
|
H411
|
GHS09
Wng
|
H411”
|
|
|
|
“616-243-00-6
|
N,N'-methyleendiacrylamide
|
203-750-9
|
110-26-9
|
Muta. 1B
|
H340
|
dGHS08
Dgr
|
H340”
|
|
|
|
“617-024-00-8
|
tert-butyl-2-ethylperoxyhexanoaat
|
221-110-7
|
3006-82-4
|
Repr. 1B
Skin Sens. 1
|
H360FD
H317
|
GHS08
GHS07
Dgr
|
H360FD
H317”
|
|
|
|